Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

11.96 -1.62 (-11.94%)
Streaming Delayed Price Updated: 1:39 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics, Inc.
Via Business Wire
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
MarketBeat Week in Review – 9/23 - 9/27
Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
Via MarketBeat
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead. 
Via MarketBeat
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.